From the Guidelines
Anoro Ellipta is not equivalent to Breo Ellipta 200/25 mcg, as they contain different active ingredients with distinct mechanisms of action. These medications are designed to treat respiratory conditions, but they have different components: Anoro Ellipta contains umeclidinium (a long-acting muscarinic antagonist) and vilanterol (a long-acting beta-agonist), while Breo Ellipta contains fluticasone furoate (an inhaled corticosteroid) and vilanterol 1. The key difference is that Breo includes an anti-inflammatory steroid component, which is not present in Anoro.
Key Differences and Considerations
- The presence of an anti-inflammatory steroid in Breo Ellipta is crucial for patients whose condition requires anti-inflammatory treatment, as removing this component could lead to worsening symptoms.
- Switching between these medications should only be done under medical supervision, considering factors such as symptom control, exacerbation history, and potential side effects 1.
- The choice between Anoro Ellipta and Breo Ellipta should be based on the individual patient's needs and the specific characteristics of their respiratory condition, as outlined in guidelines such as the 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD 1.
Clinical Implications
- Healthcare providers should evaluate the patient's specific respiratory condition and determine the most appropriate treatment, considering the benefits and risks associated with each medication.
- The decision to switch between Anoro Ellipta and Breo Ellipta should be made on a case-by-case basis, taking into account the patient's response to treatment, potential side effects, and the presence of any comorbidities.
- It is essential to prioritize the patient's morbidity, mortality, and quality of life when making decisions about their treatment regimen, as recommended by recent studies and guidelines 1.
From the Research
Anoro Ellipta and Breo Ellipta Comparison
- Anoro Ellipta contains umeclidinium and vilanterol, while Breo Ellipta contains fluticasone furoate and vilanterol.
- The dosage of Breo Ellipta 200 mcg-25mcg 1 puff daily is a combination of an inhaled corticosteroid (fluticasone furoate) and a long-acting β2-adrenoceptor agonist (vilanterol) 2, 3.
- Anoro Ellipta is a combination of a long-acting muscarinic receptor antagonist (umeclidinium) and a long-acting β2-adrenoceptor agonist (vilanterol), but it does not contain an inhaled corticosteroid.
Treatment of COPD
- Both Anoro Ellipta and Breo Ellipta are used in the treatment of chronic obstructive pulmonary disease (COPD), but they have different mechanisms of action and are used in different patient populations 4, 5.
- Triple therapy with a combination of an inhaled corticosteroid, a long-acting muscarinic receptor antagonist, and a long-acting β2-adrenoceptor agonist, such as fluticasone furoate/umeclidinium/vilanterol, has been shown to be effective in reducing exacerbations and improving lung function in patients with severe COPD 3, 6.
Equivalent Therapy
- There is no direct equivalent to Breo Ellipta 200 mcg-25mcg 1 puff daily in Anoro Ellipta, as Anoro Ellipta does not contain an inhaled corticosteroid.
- However, the combination of Anoro Ellipta (umeclidinium/vilanterol) and an inhaled corticosteroid, such as fluticasone furoate, may be considered as an alternative therapy for patients with COPD who require triple therapy 2, 4.